Skip to main content
Premium Trial:

Request an Annual Quote

Europroteome to Develop Breast Cancer Diagnostics with German Consortium

NEW YORK, June 16 - Europroteome of Hennigsdorf, Germany, has signed a research collaboration with a consortium of German academic centers to develop proteomics-based diagnostics for breast cancer, the company said today.

 

Europroteome will analyze protein expression patterns for several hundred serum samples of breast cancer patients provided by GENICA (the Interdisciplinary Study Group on Gene Environment Interaction and Breast Cancer in Germany), a national scientific network of cancer researchers in Germany.

 

The goal of the collaborative project is to develop novel non-invasive and blood-based screening tests to identify early-stage breast cancer.

 

Europroteome will correlate protein expression patterns in the serum samples with medical outcome data. The company said it recently conducted a similar study with the University of Magdeburg to use protein patterns for the identification of patients in early stages of stomach and colon cancer.

 

The first results from the GENICA project are expected over the next couple of months, Europroteome said.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.